Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.
Importance Rank:
1
Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.